D-Mannuronic acid sodium

Synonyms: D-甘露糖醛酸单糖钠
D-Mannuronic acid (β-D-Mannuronic acid) sodium 是一种口服有效的天然糖类化合物,通过抑制 MMP-2/MMP-9 活性有效抑制促炎因子和免疫抑制细胞浸润,在小鼠乳腺癌模型中发挥抗肿瘤和抗转移效果,并在阿尔茨海默病模型中改善认知、减少淀粉样斑块、抑制氧化应激和神经元凋亡 (apoptosis)。
产品编号: MS-R12477 纯度: 99.81% CAS No.: 921-56-2 分子式: C6H9NaO7 分子量: 216.12
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in Water
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
200mg
询价
询价

产品描述

D-Mannuronic acid (β-D-Mannuronic acid) sodium 是一种口服有效的天然糖类化合物,通过抑制 MMP-2/MMP-9 活性有效抑制促炎因子和免疫抑制细胞浸润,在小鼠乳腺癌模型中发挥抗肿瘤和抗转移效果,并在阿尔茨海默病模型中改善认知、减少淀粉样斑块、抑制氧化应激和神经元凋亡 (apoptosis)。

生物实验数据

生物活性 D-Mannuronic acid (β-D-Mannuronic acid) sodium is an orally effective natural carbohydrate compound that effectively inhibits pro-inflammatory factors and immunosuppressive cell infiltration by suppressing MMP-2/MMP-9 activity, exerts antitumor and antimetastatic effects in a mouse breast cancer model, and in Alzheimer's disease models improves cognition, reduces amyloid plaques, and inhibits oxidative stress and neuronal apoptosis.
体外研究
(In Vitro)

D-Mannuronic acid (5-1000 μg/mL; 48 h) sodium 对 4T1 小鼠 BALB/c 乳腺癌细胞表现出低细胞毒性,仅在 1000 μg/mL 浓度处理 48 h 后观察到细胞增殖降低。
D-Mannuronic acid (25-1000 μg/mL; 48 h) sodium 可在 4T1 小鼠 BALB/c 乳腺癌细胞中诱导剂量依赖性凋亡,在 1000 μg/mL 浓度处理 48 h 后凋亡率达 52%。
D-Mannuronic acid (25-1000 μg/mL; 48 h) sodium 可剂量依赖性地抑制 4T1 小鼠 BALB/c 乳腺癌细胞中 MMP-2 和 MMP-9 的活性。
D-Mannuronic acid (25-1000 μg/mL; 48 h) sodium 呈剂量依赖性地抑制 4T1 小鼠 BALB/c 乳腺癌细胞与 I 型胶原蛋白、纤连蛋白及层粘连蛋白的黏附。
D-Mannuronic acid sodium 在 WEHI-164 细胞中无细胞毒性。

Cell Proliferation Assay

Cell Line: 4T1 murine BALB/c breast cancer cells
Concentration: 5, 25, 250, 500 and 1000 μg/mL
Incubation Time: 48 h (treatment); 18 h ([3H]-thymidine pulse)
Result: Failed to effectively reduce 4T1 cell proliferation except at the 1000 μg/mL concentration.

Apoptosis Analysis

Cell Line: 4T1 murine BALB/c breast cancer cells
Concentration: 25, 250, 500 and 1000 μg/mL
Incubation Time: 48 h
Result: Increased 4T1 cell apoptosis in a dose-dependent manner, with apoptosis rates of 1.52%, 12%, 33%, and 52% at 25, 250, 500, and 1000 μg/mL, respectively.
体内研究
(In Vivo)

D-Mannuronic acid (25 mg/kg; i.p.; 每两天一次共 18 天) sodium 可强烈抑制小鼠乳腺癌生长、减少转移并显著延长生存期,同时还能减少炎症细胞募集及促肿瘤因子的表达。
D-Mannuronic acid (25 mg/kg/; p.o.; 每日一次共 6 周) sodium 可使阿尔茨海默病大鼠模型的空间学习、记忆及细胞凋亡标志物恢复正常,减小淀粉样斑块体积,并恢复氧化应激平衡。
D-Mannuronic acid (1000-5000 mg/kg; p.o.; 单次给药) sodium 在雄性 NMRI 小鼠中的口服 LD50 为 4.6 g/kg,在剂量高达 3000 mg/kg 时观察到 100% 的存活率。
D-Mannuronic acid (p.o.; i.p.) sodium 显著降低佐剂诱导性关节炎大鼠的足肿胀程度及关节炎组织病理学损伤。
D-Mannuronic acid sodium 可发挥免疫抑制作用,显著减轻实验性自身免疫性脑脊髓炎大鼠的临床症状和组织学损伤。
D-Mannuronic acid sodium 可显著改善免疫复合物型肾小球肾炎和实验性肾病大鼠的肾功能指标,并减轻其肾小球损伤。

Animal Model: BALB/c (6- to 8-week-old female, 18-20 g, inoculated with 5×105 4T1 murine breast cancer cells into mammary fat pad)
Dosage: 25 mg/kg (therapeutic group)
Administration: i.p.; every 2 days; day 8 to day 26 post-tumor inoculation
Result: Reduced tumor volume by 86.5% compared to control at day 30 post-inoculation.
Reduced lung metastatic area by 77.8% compared to control at day 30 post-inoculation.
Extended mean survival time to exceed 120 days.
Showed tumor tissue with low mitotic rate (1 mitosis/high-power field), small areas of neutrophilic inflammation, and necrosis limited to the tumor edge.
Significantly reduced spleen myeloid-derived suppressor cell (MDSC) frequency, lymph node regulatory T (Treg) cell frequency, white blood cell count, neutrophil ratio, serum IL-1β, and serum IL-6 levels compared to control.
Substantially reduced mRNA expression of inflammatory chemokines (S100A8, S100A9, CCL22, CCL2, CCL9) and tumor-promoting factors (TGFβ, VEGF, MMP-2, MMP-9, HIF-1α) in tumor tissue compared to control.
Animal Model: Wistar rats (male, 180-220 g, intrahippocampal injection of aggregated Aβ1-42)
Dosage: 25 mg/kg/d
Administration: p.o.; daily; 6 weeks
Result: Significantly reduced escape latency and distance traveled in the Morris water maze, with values matching control levels.
Significantly increased time spent in the target quadrant during probe trial, matching control levels.
Significantly reduced amyloid plaque size in the hippocampus relative to Aβ-only rats, with improved cell morphology.
Significantly reduced Bax/Bcl2 ratio compared to Aβ-only rats, matching control levels.
Significantly increased procaspase-3 expression compared to Aβ-only rats, returning to near-control levels.
Significantly reduced P53 expression compared to Aβ-only rats, matching control levels.
Significantly reduced superoxide dismutase (SOD) activity compared to Aβ-only rats, returning to control levels.
Reduced malondialdehyde (MDA) levels relative to Aβ-only rats, though remained slightly elevated compared to controls.
Showed no significant difference in catalase (CAT) activity from control or Aβ-only rats.
性状 固体
颜色 White to yellow

化学信息

分子量 216.12
分子式 C6H9NaO7
CAS No. 921-56-2
别名 D-甘露糖醛酸单糖钠

储存&溶解度

储存方式

4°C, sealed storage, away from moisture

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

H2O 中的溶解度 : ≥ 100 mg/mL (462.71 mM)

* "≥" means soluble, but saturation unknown.

可选溶剂浓度1 mg5 mg10 mg25 mg
H2O1 mM4.6271 mL23.1353 mL46.2706 mL115.6765 mL
5 mM0.9254 mL4.6271 mL9.2541 mL23.1353 mL
10 mM0.4627 mL2.3135 mL4.6271 mL11.5676 mL
15 mM0.3085 mL1.5424 mL3.0847 mL7.7118 mL
20 mM0.2314 mL1.1568 mL2.3135 mL5.7838 mL
25 mM0.1851 mL0.9254 mL1.8508 mL4.6271 mL
30 mM0.1542 mL0.7712 mL1.5424 mL3.8559 mL
40 mM0.1157 mL0.5784 mL1.1568 mL2.8919 mL
50 mM0.0925 mL0.4627 mL0.9254 mL2.3135 mL
60 mM0.0771 mL0.3856 mL0.7712 mL1.9279 mL
80 mM0.0578 mL0.2892 mL0.5784 mL1.4460 mL
100 mM0.0463 mL0.2314 mL0.4627 mL1.1568 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础